23-Hydroxybetulinic acid

Synonyms: 23-羟基白桦酸; Anemosapogenin
23-Hydroxybetulinic acid (Anemosapogenin) 是一种具有口服活性和广谱抗癌活性的三萜类化合物,可降低 Bcl-2 和 survivin 水平、升高 Bax 水平、促进 caspase-3 和 caspase-9 的剪切/活化,并通过包括细胞色素 C 释放和线粒体膜电位破坏在内的内源性线粒体通路诱导细胞凋亡 (apoptosis),同时可将细胞周期阻滞于 S 和 G1 期、抑制癌细胞增殖、阻断 MAPK 信号通路、调控 MMP2 并通过上调 beclin-1 诱导自噬性凋亡,还可抑制 P-gp 的活性和外排功能、增加细胞内化疗药物的蓄积量并与 Doxorubicin (MS-B38737) 协同增强细胞毒性,以及抑制 STAT6 的磷酸化和核转位、阻断 M2 型巨噬细胞极化、降低 M2 型巨噬细胞介导的结肠癌细胞凋亡抵抗,可用于慢性髓系白血病、肝细胞癌、肉瘤 180 癌、多药耐药乳腺癌、Doxorubicin 诱导的心脏毒性以及结直肠癌的相关研究。
产品编号: MS-N42886 纯度: 99.44% CAS No.: 85999-40-2 分子式: C30H48O4 分子量: 472.70
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

23-Hydroxybetulinic acid (Anemosapogenin) 是一种具有口服活性和广谱抗癌活性的三萜类化合物,可降低 Bcl-2 和 survivin 水平、升高 Bax 水平、促进 caspase-3 和 caspase-9 的剪切/活化,并通过包括细胞色素 C 释放和线粒体膜电位破坏在内的内源性线粒体通路诱导细胞凋亡 (apoptosis),同时可将细胞周期阻滞于 S 和 G1 期、抑制癌细胞增殖、阻断 MAPK 信号通路、调控 MMP2 并通过上调 beclin-1 诱导自噬性凋亡,还可抑制 P-gp 的活性和外排功能、增加细胞内化疗药物的蓄积量并与 Doxorubicin (MS-B38737) 协同增强细胞毒性,以及抑制 STAT6 的磷酸化和核转位、阻断 M2 型巨噬细胞极化、降低 M2 型巨噬细胞介导的结肠癌细胞凋亡抵抗,可用于慢性髓系白血病、肝细胞癌、肉瘤 180 癌、多药耐药乳腺癌、Doxorubicin 诱导的心脏毒性以及结直肠癌的相关研究。

生物实验数据

生物活性 23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid compound with broad-spectrum anticancer activity that reduces Bcl-2 and survivin levels, increases Bax levels, promotes caspase-3 and caspase-9 cleavage/activation, and induces apoptosis through the intrinsic mitochondrial pathway involving cytochrome C release and disruption of mitochondrial membrane potential, while also arresting the cell cycle at S and G1 phases, inhibiting cancer cell proliferation, blocking the MAPK signaling pathway, regulating MMP2, and inducing autophagic apoptosis via upregulation of beclin-1, and it further inhibits P-gp activity and efflux function, increases intracellular accumulation of chemotherapeutic drugs, synergistically enhances cytotoxicity with Doxorubicin (MS-B38737), inhibits STAT6 phosphorylation and nuclear translocation, blocks M2-type macrophage polarization, reduces M2-type macrophage-mediated apoptosis resistance in colon cancer cells, and can be used for research on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180 carcinoma, multidrug-resistant breast cancer, Doxorubicin-induced cardiotoxicity, and colorectal cancer.
IC50 & Target

Caspase 3

 

Caspase-9

 

Bax

 

Bcl-2

 

MMP-2

 

体外研究
(In Vitro)

23-Hydroxybetulinic acid (0-300 μM; 48 h) 可强效抑制人慢性粒细胞白血病 K562 细胞的增殖 (IC50 = 39.9 μM),且对 B16、HeLa 和 HUVEC 细胞的细胞毒性较低。
23-Hydroxybetulinic acid (0-80 μM; 24 h) 可在处理 24 h 后诱导人慢性粒细胞白血病 K562 细胞发生浓度依赖性的 S 期细胞周期阻滞,其中 80 μM HBA 可将 S 期细胞比例提升至 52.34%。
23-Hydroxybetulinic acid (20-80 μM; 24 h) 经 Hoechst33342/PI 双染色检测显示,处理 24 h 后可在人慢性粒细胞白血病 K562 细胞中诱导浓度依赖性凋亡。
23-Hydroxybetulinic acid (20-80 μM; 24 h) 可显著破坏人慢性粒细胞白血病 K562 细胞的线粒体膜电位,经 24 h 处理后,80 μM HBA 可将红/绿荧光比率降至 0.38。
23-Hydroxybetulinic acid (10-80 μM; 24 h) 可在作用 24 小时后诱导人慢性粒细胞白血病 K562 细胞激活内源性 (线粒体) 凋亡通路,其机制为通过浓度依赖性方式调控促凋亡与抗凋亡蛋白,并激活胱天蛋白酶。
23-Hydroxybetulinic acid (1.25-20 μM; 48-72 h) 可呈时间和浓度依赖性抑制 Huh-7、Hep3B 和 Li-7 人肝癌细胞的活力,其中以 20 μM 作用 72 h 时对 Huh-7 细胞的抑制效果最强。
23-Hydroxybetulinic acid (1.25-20 μM; 2-3 weeks) 可在 2-3 周内抑制人肝癌细胞 Huh-7、Hep3B 和 Li-7 的集落形成,其中对 Huh-7 细胞的作用效果最强。
23-Hydroxybetulinic acid (5-20 μM; 48 h) 可呈浓度依赖性诱导人肝癌 Huh-7 细胞凋亡,且该效应可被 Bcl-2 过表达逆转。
23-Hydroxybetulinic acid (5-20 μM) 可调控人肝癌 Huh-7 细胞中凋亡相关蛋白的表达,以浓度依赖的方式上调 Bax,并下调 Bcl-2 与活化型 caspase-3。
23-Hydroxybetulinic acid (5-20 μM) 可调控人肝癌 Huh-7 细胞的迁移/侵袭以及 MAPK 通路相关蛋白的表达,以浓度依赖的方式降低 MMP2、MMP9、p-MEK1/2 和 p-ERK1/2 的水平,同时上调 TIMP2 的表达。
23-Hydroxybetulinic acid (5-20 μM; 48 h) 可呈浓度依赖性抑制人肝癌 Huh-7 细胞的迁移和侵袭能力。
23-Hydroxybetulinic acid (48 h) 可剂量依赖性地抑制 NCI-H460、SGC7901、HepG2 及肉瘤 180 细胞的生长,其平均 IC50 值分别为 49.2 μM、49.1 μM、306.4 μM 和 28.0 μM。
23-Hydroxybetulinic acid (0.2-20 μM; 48 h) 可呈剂量依赖性地增强 Driamaycin 对过表达 P-gp 的人乳腺癌细胞 MCF-7/ADR 的细胞毒性,降低细胞存活率。
23-Hydroxybetulinic acid (0.2-20 μM; 48 h) 可呈剂量依赖性地增强 VCR 对过表达 P-gp 的人乳腺癌细胞 MCF-7/ADR 的细胞毒性,降低细胞存活率。
23-Hydroxybetulinic acid (2-20 μM) 可呈剂量依赖性地增强 ADR 诱导的过表达 P-糖蛋白 (P-gp) 的人乳腺癌细胞 MCF-7/ADR 的凋亡。
23-Hydroxybetulinic acid (0.2-20 μM; 1 h) 可剂量依赖性地增加过表达 P-gp 的人乳腺癌 MCF-7/ADR 细胞内的 ADR 蓄积。
23-Hydroxybetulinic acid (0.2-20 μM; 1 h) 可剂量依赖性地增加过表达 P-gp 的人乳腺癌细胞 MCF-7/ADR 中的细胞内 VCR 蓄积。
23-hydroxybetulinic acid (6.25-100 μM; 6, 12, 24, 48 h) 可呈剂量和时间依赖性强效抑制 HL-60 细胞增殖,在 48 h 时的 IC50 为 20.12 μM。
23-hydroxybetulinic acid (12.5 μM; 24 h) 可诱导 HL-60 细胞中自噬小泡的形成。
23-hydroxybetulinic acid (12.5-50 μM; 24 h) 可将 HL-60 细胞阻滞于细胞周期的 G1 期,且随着浓度升高,G1 期细胞占比增加。
23-hydroxybetulinic acid (12.5-50 μM; 6, 12, 24 h) 可在体外以时间和剂量依赖的方式诱导 HL-60 细胞发生自噬性凋亡,在测试的浓度和时间范围内,其凋亡率为 11.60% 至 78.73%。
23-hydroxybetulinic acid 可在体外以剂量依赖方式上调 HL-60 细胞中 beclin-1 的 mRNA 表达水平。
23-Hydroxybetulinic acid (0.2-20 μM; 24 h) 可浓度依赖性地减轻 Doxorubicin 对大鼠 H9c2 细胞的细胞毒性,在 0.2、2 和 20 μM (for 24 h) 的浓度下,分别将 Doxorubicin 的 IC50 提升至 12.94、17.67 和 26.55 μM。
23-Hydroxybetulinic acid (2.5-40 μM; 48 h) 在孵育 48 h 后,浓度高达 20 μM 时对 THP-1 来源的 M0 巨噬细胞无毒性。
23-Hydroxybetulinic acid (10-20 μM; 48 h) 可浓度依赖性地抑制 IL-4 诱导的 THP-1 来源巨噬细胞向 M2 型极化,该作用通过孵育 48 h 后 CD206 表达水平降低得到验证。
23-Hydroxybetulinic acid (10-20 μM; 48 h) 可浓度依赖性地下调经 IL-4 刺激的 THP-1 来源巨噬细胞中 M2 相关基因 (CD206、Arg1、IL-10、CCL2) 的 mRNA 水平,孵育时长为 48 h。
23-Hydroxybetulinic acid (10-20 μM; 48 h) 呈浓度依赖性抑制 IL-4 诱导的 THP-1 来源巨噬细胞中 STAT6 的磷酸化与核转位,其作用机制为直接结合 STAT6。
23-Hydroxybetulinic acid (20 μM; 48 h) 以依赖 STAT6 的方式抑制 IL-4 诱导的 THP-1 来源巨噬细胞向 M2 型极化,该实验在与 IL-4 共同孵育 48 h 后开展。
23-Hydroxybetulinic acid (10-20 μM; 48 h) 可浓度依赖性地抑制 THP-1 来源巨噬细胞中由 IL-4 诱导的 IL-10 分泌;该检测是在 23-HBA 孵育 48 h 后,经无血清培养 72 h 的条件培养基中完成的。
23-Hydroxybetulinic acid (20 μM; 48 h) 可抑制经 23-HBA 处理的巨噬细胞条件培养基中培养、且经 5-FU 孵育 48 h 的 SW480 结直肠癌细胞中的 IL-10/STAT3/Bcl-2 信号通路。

Cell Cytotoxicity Assay

Cell Line: human chronic myelogenous leukemia K562 cells, mouse melanoma B16 cells, human cervical carcinoma HeLa cells, human umbilical vein endothelial HUVEC cells
Concentration: 0-300 μM
Incubation Time: 48 h
Result: Inhibited proliferation of K562 cells with an IC50 of 39.9 μM, B16 cells with an IC50 of 78.5 μM, HeLa cells with an IC50 of 80.0 μM, and HUVEC cells with an IC50 of 94.8 μM.
Caused decreased cell population and morphological shrinkage in K562 cells.

Cell Cycle Analysis

Cell Line: human chronic myelogenous leukemia K562 cells
Concentration: 20 μM; 40 μM; 80 μM
Incubation Time: 24 h
Result: Increased the percentage of K562 cells in S phase from 26.35% (untreated) to 31.6%, 32.81%, and 52.34% at 20, 40, and 80 μM, respectively.
Reduced G0/G1 and G2/M phase populations in a concentration-dependent manner.

Apoptosis Analysis

Cell Line: human chronic myelogenous leukemia K562 cells
Concentration: 20 μM; 40 μM; 80 μM
Incubation Time: 24 h
Result: Caused concentration-dependent increases in nuclear condensation (bright blue fluorescence) and uptake of PI (red fluorescence, indicating necrotic/advanced apoptotic cells) in K562 cells.\nIncreased total apoptotic K562 cells to 8.3%, 11.4%, and 18.2% at 20, 40, and 80 μM, respectively, compared to 3.8% in untreated cells.

Western Blot Analysis

Cell Line: human chronic myelogenous leukemia K562 cells
Concentration: 10 μM; 20 μM; 40 μM; 80 μM
Incubation Time: 24 h
Result: Increased pro-apoptotic Bax, cytosolic cytochrome C, cleaved caspase-9, and cleaved caspase-3 levels in a concentration-dependent manner.
Decreased anti-apoptotic Bcl-2 and survivin levels in a concentration-dependent manner.

Cell Viability Assay

Cell Line: Huh-7, Hep3B, Li-7 (human hepatocellular carcinoma cell lines)
Concentration: 1.25 μM; 2.5 μM; 5 μM; 10 μM; 20 μM
Incubation Time: 48 h; 72 h
Result: Significantly inhibited viability of Huh-7, Hep3B, and Li-7 cells in a time- and concentration-dependent manner.
Caused a more pronounced decline in cell viability at 20 μM for 72 h than for 48 h, with the strongest inhibitory effect observed in Huh-7 cells.

Apoptosis Analysis

Cell Line: Huh-7 (human hepatocellular carcinoma cell line)
Concentration: 5 μM; 10 μM; 20 μM
Incubation Time: 48 h
Result: Caused dose-dependent nuclear shrinkage, cytoplasmic/nuclear fractionation, and formation of apoptotic bodies in Huh-7 cells, with increased numbers of apoptotic cells at higher concentrations.\nIncreased the apoptosis rate of Huh-7 cells in a concentration-dependent manner.
Had its pro-apoptotic effect reversed by overexpression of Bcl-2.

Cell Migration Assay

Cell Line: Huh-7 (human hepatocellular carcinoma cell line)
Concentration: 5 μM; 10 μM; 20 μM
Incubation Time: 48 h
Result: Inhibited migration of Huh-7 cells in a concentration-dependent manner, with more pronounced inhibition at higher concentrations.

Cell Invasion Assay

Cell Line: Huh-7 (human hepatocellular carcinoma cell line)
Concentration: 5 μM; 10 μM; 20 μM
Incubation Time: 48 h
Result: Inhibited invasion of Huh-7 cells in a concentration-dependent manner, with more pronounced inhibition at higher concentrations.

Cell Autophagy Assay

Cell Line: HL-60
Concentration: 12.5 μM
Incubation Time: 24 h
Result: Induced formation of numerous autophagic vacuoles and empty vacuoles in treated cells.

Apoptosis Analysis

Cell Line: HL-60
Concentration: 12.5-50 μM
Incubation Time: 6, 12, 24 h
Result: Induced autophagic apoptosis with rates of 11.60% (12.5 μM, 6 h), 17.49% (12.5 μM, 12 h), 28.37% (12.5 μM, 24 h), 25.90% (25 μM, 6 h), 49.00% (25 μM, 12 h), 72.20% (25 μM, 24 h), 28.17% (50 μM, 6 h), 60.69% (50 μM, 12 h), 78.73% (50 μM, 24 h).

Cell Viability Assay

...(内容过长已截断)
Cell Line: rat H9c2 cells
体内研究
(In Vivo)

23-Hydroxybetulinic acid (10-20 mg/kg/天;每日给药;持续 4 周) 可在裸鼠中呈剂量依赖性地抑制肝细胞癌的肿瘤生长、肺转移及免疫抑制,其中 20 mg/kg 剂量可实现肺转移的近乎完全清除,且未表现出明显的毒性作用。
23-Hydroxybetulinic acid (20-100 mg/kg;灌胃;每日一次;连续 7 天;联合给药时于 Doxorubicin (MS-B38737) 给药前 1 小时给予) 单独使用对荷肉瘤 180 小鼠无显著体内抗肿瘤活性,但与 Doxorubicin 联用时可产生协同抗肿瘤效应 (20 mg/kg 和 100 mg/kg 剂量下分别使肿瘤重量降低 52%和 59%),增加肿瘤内 Doxorubicin 的蓄积量,抑制 Doxorubicin 诱导的 P-gp 上调,并缓解 Doxorubicin 诱导的心脏毒性。
23-Hydroxybetulinic acid (20-80 mg/kg/day;灌胃;每日) 可剂量依赖性地缓解 Doxorubicin 诱导的雄性 Balb/c 小鼠心脏毒性,其中 80 mg/kg/day 口服剂量可使心脏中 Doxorubicin 的蓄积量降低 46.52%,并将左心室射血分数改善至 75.68%。
23-Hydroxybetulinic acid (7.5-15 mg/kg;腹腔注射;每日一次) 可在小鼠中通过 STAT6 信号通路抑制 M2 型巨噬细胞极化,单独使用时可轻度降低结直肠癌肿瘤重量,与 5-Fluorouracil (5-FU) (HY-90006) 联用时可将其抗肿瘤疗效提升约 80%,且无明显毒性。

Animal Model: BALB/c nude mice (male, 4-6 weeks old, 18-20 g, subcutaneously injected with HCC cells)
Dosage: 10 mg/kg/day; 20 mg/kg/day
Administration: daily; 4 weeks
Result: Reduced tumor volume and weight, with 20 mg/kg producing a more pronounced decline.
Reduced positive expression of Ki-67, MMP2, and MMP9, and increased positive expression of cleaved caspase-3 in tumor tissues of mice treated with 20 mg/kg.
Reduced the number of metastatic lung nodules in mice treated with 10 mg/kg, and eliminated almost all lung nodules in mice treated with 20 mg/kg.
Reduced the percentage of CD11b+Gr1+ myeloid-derived suppressor cells (MDSCs) in a concentration-dependent manner.
Caused no obvious body weight loss or pathological lesions in heart, liver, spleen, lung, or kidney tissues with either dose.
Animal Model: ICR (male, 18-22 g)
Dosage: 20 mg/kg; 100 mg/kg
Administration: i.g.; daily; 7 consecutive days; 1 hour prior to Doxorubicin when in combination
Result: Exerted no significant inhibitory effects on tumor weight when administered alone at 20 mg/kg or 100 mg/kg.
Reduced tumor weight by 52% when co-administered with Doxorubicin at 20 mg/kg.
Reduced tumor weight by 59% when co-administered with doxorubicin at 100 mg/kg; both combination groups showed significantly better therapeutic efficacy than Doxorubicin alone.
Dose-dependently increased intra-tumor Doxorubicin concentration, with the 100 mg/kg dose producing a statistically significant increase.
Had no effect on P-gp expression in tumors when administered alone.
Significantly prevented doxorubicin-induced up-regulation of P-gp expression at 20 mg/kg and 100 mg/kg.
Resulted in normal cardiac morphology when used in combination treatment, alleviating Doxorubicin-induced myocardial hemorrhagic spots.
Caused no significant differences in mouse body weight across groups.
Animal Model: BALB/c (male, 6-8 weeks old, 20±2 g, subcutaneous injection of 2×106 CT26 cells)
Dosage: 7.5 mg/kg; 15 mg/kg
Administration: i.p. (daily); i.p. (once every 3 days, 5-FU)
Result: Slightly reduced tumor weight at 7.5 mg/kg or 15 mg/kg monotherapy.
Reduced tumor weight by approximately 80% when co-administered with 5-FU at 15 mg/kg compared to the model group.
Significantly reduced tumor weight when co-administered with 5-FU at 7.5 mg/kg compared to the model group.
Did not cause significant changes in body weight, thymus index, or spleen index with monotherapy and co-treatment compared to relevant control groups.
Significantly reduced the percentage of p-STAT6-positive area and CD206-positive area in tumor tissues at 7.5 mg/kg and 15 mg/kg compared to the model group.
Induced significantly lower IL-10 mRNA levels and Bcl-2 expression in tumor tissues in the 15 mg/kg plus 5-FU group compared to the 5-FU monotherapy group.
性状 固体
颜色 White to off-white

化学信息

分子量 472.70
分子式 C30H48O4
CAS No. 85999-40-2
别名 23-羟基白桦酸; Anemosapogenin

储存&溶解度

体内实验配方
10% DMSO+90% Saline: < 10 mg/mL (21.16 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+90% Corn Oil: 2.5 mg/mL (5.29 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (21.16 mM), Suspension.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

-20°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (211.55 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1155 mL10.5775 mL21.1551 mL52.8877 mL
5 mM0.4231 mL2.1155 mL4.2310 mL10.5775 mL
10 mM0.2116 mL1.0578 mL2.1155 mL5.2888 mL
15 mM0.1410 mL0.7052 mL1.4103 mL3.5258 mL
20 mM0.1058 mL0.5289 mL1.0578 mL2.6444 mL
25 mM0.0846 mL0.4231 mL0.8462 mL2.1155 mL
30 mM0.0705 mL0.3526 mL0.7052 mL1.7629 mL
40 mM0.0529 mL0.2644 mL0.5289 mL1.3222 mL
50 mM0.0423 mL0.2116 mL0.4231 mL1.0578 mL
60 mM0.0353 mL0.1763 mL0.3526 mL0.8815 mL
80 mM0.0264 mL0.1322 mL0.2644 mL0.6611 mL
100 mM0.0212 mL0.1058 mL0.2116 mL0.5289 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础

  • 客服

    2851296953

    18923798467

    微信洽谈